PolyPid grants CFO options for 49,000 shares

PolyPid Ltd. reported that Chief Financial Officer Jonathan Missulawin received a grant of stock options for 49,000 Ordinary Shares on May 11, 2026.

Accepted by SEC EDGAR 07/17/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. reported that Chief Financial Officer Jonathan Missulawin received a grant of stock options for 49,000 Ordinary Shares on May 11, 2026. The options have an exercise price of $4.46 per share, an exercise date of August 11, 2026, and expire on May 11, 2036. According to the vesting terms, they vest on a quarterly basis beginning May 11, 2026 until May 11, 2030, leaving him with 49,000 options outstanding.

Insider Trade Summary

Grant/Award: 49,000 shares

Grant/Award 1 txn

Insider Missulawin Jonathan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	49,000	$4.46	$219K

Holdings After Transaction: Stock option (right to buy) — 49,000 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 49,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

Key Figures

Stock options granted: 49,000 options Exercise price: $4.46 per share Underlying Ordinary Shares: 49,000 shares +4 more

7 metrics

Stock options granted 49,000 options Grant to CFO Jonathan Missulawin on 2026-05-11

Exercise price $4.46 per share Exercise price for the 49,000 stock options

Underlying Ordinary Shares 49,000 shares Shares underlying the granted stock options

Total options held after grant 49,000 options Directly held derivative securities following the reported transaction

Exercise date 2026-08-11 Reported exercise date for the granted options

Expiration date 2036-05-11 Expiration date of the stock options

Vesting period May 11, 2026–May 11, 2030 Options vest quarterly over this four-year period

Key Terms

Stock option (right to buy), exercise date, expiration date, vest on a quarterly basis

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise date financial

"exercise_date: 2026-08-11 is the exercise date"

expiration date financial

"expiration_date: 2036-05-11 is the expiration date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest on a quarterly basis financial

"The options vest on a quarterly basis beginning May 11, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PolyPid (PYPD) report for its CFO?

PolyPid reported a grant to CFO Jonathan Missulawin of stock options covering 49,000 Ordinary Shares. The award was dated May 11, 2026, with an exercise price of $4.46 per share, an exercise date of August 11, 2026, and an expiration date of May 11, 2036.

What are the key terms of the PolyPid (PYPD) stock options granted to the CFO?

The CFO received 49,000 stock options with an exercise price of $4.46 per share. They have an exercise date of August 11, 2026 and expire on May 11, 2036, providing a long-dated incentive linked to PolyPid’s Ordinary Shares.

How do the PolyPid (PYPD) CFO’s stock options vest?

According to the terms, the options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030. This creates a four-year vesting schedule, with portions of the 49,000 options becoming exercisable each quarter over that period.

How many PolyPid (PYPD) options does the CFO hold after this grant?

After the transaction, the CFO is reported to beneficially hold 49,000 stock options directly. These options are linked to 49,000 underlying Ordinary Shares, all from this single grant dated May 11, 2026.

Was the PolyPid (PYPD) CFO’s option grant made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the transaction is categorized as a grant or award, not an open-market trade executed under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Missulawin Jonathan

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	05/11/2026		A		49,000		08/11/2026(1)	05/11/2036	Ordinary Shares	49,000	$4.46	49,000	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

	/s/ Missulawin Jonathan	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)